【摘要】 目的:评价厄罗替尼一线治疗中晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)老年患者的疗效和安全性。方法:2007年5月—2008年12月首次确诊的35例70～81岁中晚期NSCLC老年患者,其中鳞状细胞癌18例、腺癌13例、细支气管肺泡癌4例;吸烟者19例,不吸烟者16例。所有患者均接受厄罗替尼150mg/d口服治疗,直至疾病进展或出现无法耐受的不良反应。对所有患者均进行随访,观察近期疗效和不良反应,并计算生存情况。结果:35例患者中,1例获得完全缓解,16例获得部分缓解,10例疾病稳定,8例疾病进展;总有效率为48.6%(17/35),疾病控制率为77.1%(27/35)。中位至疾病进展时间为6.4个月,中位总生存期为12.7个月,1年生存率为48.6%(17/35)。性别、病理类型和吸烟史与疾病控制率相关(P<0.05)。不良反应主要为皮疹和腹泻,只有1例患者因较为严重的皮疹和腹泻而减少厄罗替尼剂量。结论:厄罗替尼一线治疗中晚期NSCLC老年患者可取得较好的疾病控制率和临床获益,不良反应可以耐受。更多还原

【Abstract】 Objective:To evaluate the efficacy and safety of erlotinib as first-line treatment for the elderly patients with advanced non-small cell lung cancer(NSCLC).Methods:Thirty-five elderly patients(70-80 years of age) with initial diagnosis of advanced NSCLC confirmed by pathological examinations between May 2007 and December 2008 were recruited into this prospective study,including squamous-cell carcinoma in 18 patients,adenocarcinoma in 13 patients,and bronchioloalveolar carcinoma in 4 patients.Of these 35 patients,19 had a history of smoking,and 16 were non-smokers.All patients received erlotinib(150 mg/d) as first-line treatment which was continued until disease progression or intolerable toxicity occurred.The short-term response and the adverse reactions were observed.The follow-up was performed,and the survival was analyzed.Results:Of the 35 patients,1 patient had complete response,16 patients had partial response,10 patients had stable disease,and 8 patients had progressive disease;the overall response rate was 48.6%(17/35),and the disease control rate was 77.1%(27/35).The median time to progression was 6.4 months,and the median overall survival was 12.7 months;the one-year survival rate was 48.6%(17/35).The factors of gender,pathology and smoking history were associated with the disease control rate(P<0.05).The major erlotinib-related adverse reactions were rash and diarrhea,and the dose of erlotinib was reduced in only one patient due to severe rash and diarrhea.Conclusion:The elderly patients with advanced NSCLC have clinical benefits of erlotinib as first-line treatment,and the disease control rate and the clinical benefit rate are both acceptable,as well as the adverse reactions are tolerable.更多还原